{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:29:01Z","timestamp":1770434941632,"version":"3.49.0"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2010,3,24]],"date-time":"2010-03-24T00:00:00Z","timestamp":1269388800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1007\/s11095-010-0112-z","type":"journal-article","created":{"date-parts":[[2010,3,23]],"date-time":"2010-03-23T22:18:22Z","timestamp":1269382702000},"page":"1184-1202","source":"Crossref","is-referenced-by-count":25,"title":["Drug Delivery Systems and Liver Targeting for the Improved Pharmacotherapy of the Hepatitis B Virus (HBV) Infection"],"prefix":"10.1007","volume":"27","author":[{"given":"Mar\u00eda L.","family":"Cuestas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica L.","family":"Mathet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 R.","family":"Oubi\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Sosnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,3,24]]},"reference":[{"key":"112_CR1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/epirev\/mxj009","volume":"28","author":"CW Shepard","year":"2006","unstructured":"Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006;28:112\u201325.","journal-title":"Epidemiol Rev."},{"key":"112_CR2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/(SICI)1096-9071(199909)59:1<19::AID-JMV4>3.0.CO;2-B","volume":"59","author":"PF Coleman","year":"1999","unstructured":"Coleman PF, Chen YC, Mushahwar IK. Immunoassay detection of hepatitis B surface antigen mutants. J Med Virol. 1999;59:19\u201324.","journal-title":"J Med Virol."},{"key":"112_CR3","unstructured":"Hepatitis B: World Health Organization Fact Sheet 204. http:\/\/www.who.int\/mediacentre\/factsheets\/fs204\/en\/ (accessed 01\/17\/2000)."},{"key":"112_CR4","first-page":"9","volume":"25","author":"AS Lok","year":"2002","unstructured":"Lok AS. Chronic hepatitis B. N Engl J Med. 2002;25:9\u201319.","journal-title":"N Engl J Med."},{"key":"112_CR5","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.cld.2007.08.008","volume":"11","author":"RG Gish","year":"2007","unstructured":"Gish RG, Locarnini S. Genotyping and genomic sequencing in clinical practice. Clin Liver Dis. 2007;11:761\u201395.","journal-title":"Clin Liver Dis."},{"key":"112_CR6","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1016\/S1386-6532(05)80020-4","volume":"34","author":"T Asselah","year":"2005","unstructured":"Asselah T, Ripault M-P, Castelnau C, Giuily N, Boyer N, Marcellin P. The current status of antiviral therapy of chronic hepatitis B. J Clin Virol. 2005;34:S115\u201324.","journal-title":"J Clin Virol."},{"key":"112_CR7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3748\/wjg.v13.i1.8","volume":"13","author":"D Glebe","year":"2007","unstructured":"Glebe D. Recent advances in hepatitis B virus research: a German point of view. World J Gastroenterol. 2007;13:8\u201313.","journal-title":"World J Gastroenterol."},{"key":"112_CR8","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","volume":"351","author":"YF Liaw","year":"2004","unstructured":"Liaw YF, Sung JJ, Chow WG, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521\u201331.","journal-title":"N Engl J Med."},{"key":"112_CR9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3748\/wjg.v13.i1.125","volume":"13","author":"HL Tillmann","year":"2007","unstructured":"Tillmann HL. Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol. 2007;13:125\u201340.","journal-title":"World J Gastroenterol."},{"key":"112_CR10","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1177\/135965350701200816","volume":"12","author":"MF Yuen","year":"2007","unstructured":"Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW. et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antiv Ther. 2007;12:1295\u2013303.","journal-title":"Antiv Ther."},{"key":"112_CR11","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0016-5085(03)00939-9","volume":"125","author":"P Angus","year":"2003","unstructured":"Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology. 2003;125:292\u20137.","journal-title":"Gastroenterology"},{"key":"112_CR12","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.1128\/JVI.00366-08","volume":"82","author":"KA Zimmerman","year":"2008","unstructured":"Zimmerman KA, Fischer KP, Joyce MA, Tyrrell DLJ. Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture. J Virol. 2008;82:8013\u201321.","journal-title":"J Virol."},{"key":"112_CR13","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0169-409X(01)00109-0","volume":"47","author":"PCN Rensen","year":"2001","unstructured":"Rensen PCN, De Vrueh RLA, Kuiper J. Recombinant lipoproteins: iipoprotein-like lipid particles for drug trageting. Adv Drug Deliv Rev. 2001;47:251\u201376.","journal-title":"Adv Drug Deliv Rev."},{"key":"112_CR14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/infdis\/135.1.79","volume":"135","author":"WH Bancroft","year":"1977","unstructured":"Bancroft WH, Snitbhan R, Scott RM, Tingpalapong M, Watson WT, Tanticharoenyos P, et al. Transmission of hepatitis B virus to gibbons by exposure to human saliva containing hepatitis B surface antigen. J Infect Dis. 1977;135:79\u201385.","journal-title":"J Infect Dis."},{"key":"112_CR15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/infdis\/142.1.67","volume":"142","author":"RM Scott","year":"1980","unstructured":"Scott RM, Snitbhan R, Bancroft WH, Alter HJ, Tingpalapong M. Experimental transmission of hepatitis B virus by semen and saliva. J Infect Dis. 1980;142:67\u201371.","journal-title":"J Infect Dis."},{"key":"112_CR16","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.cld.2007.08.002","volume":"11","author":"TM Block","year":"2007","unstructured":"Block TM, Guo H, Guo J-T. Molecular virology of hepatitis B virus for clinicians. Clin Liver Dis. 2007;11:685\u2013706.","journal-title":"Clin Liver Dis."},{"key":"112_CR17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.iy.13.040195.000333","volume":"13","author":"FV Chisari","year":"1995","unstructured":"Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol. 1995;13:29\u201360.","journal-title":"Annu Rev Immunol."},{"key":"112_CR18","doi-asserted-by":"crossref","first-page":"9369","DOI":"10.1128\/JVI.79.15.9369-9380.2005","volume":"79","author":"SF Wieland","year":"2005","unstructured":"Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol. 2005;79:9369\u201380.","journal-title":"J Virol."},{"key":"112_CR19","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2005.12.022","volume":"45","author":"D Sprengers","year":"2006","unstructured":"Sprengers D, van der Molen RG, Kusters JG, De Man RA, Niesters HG, Schalm SW, et al. Analysis of intrahepatic HBV-specific cytotoxic T-cells during and after acute HBV infection in humans. J Hepatol. 2006;45:182\u20139.","journal-title":"J Hepatol."},{"key":"112_CR20","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cld.2007.08.001","volume":"11","author":"JM Vierling","year":"2007","unstructured":"Vierling JM. The immunology of hepatitis B. Clin Liver Dis. 2007;11:727\u201359.","journal-title":"Clin Liver Dis."},{"issue":"Suppl 4","key":"112_CR21","doi-asserted-by":"crossref","first-page":"A80","DOI":"10.1016\/S0264-410X(02)00392-4","volume":"20","author":"LG Guidotti","year":"2002","unstructured":"Guidotti LG. The role of cytotoxic T cells and cytokines in the control of hepatitis B virus infection. Vaccine. 2002;20 Suppl 4:A80\u20132.","journal-title":"Vaccine."},{"key":"112_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(99)00056-X","volume":"44","author":"F Zoulim","year":"1999","unstructured":"Zoulim F. Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies. Antiviral Res. 1999;44:1\u201330.","journal-title":"Antiviral Res."},{"issue":"4","key":"112_CR23","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2007.01.007","volume":"46","author":"M Iannacone","year":"2007","unstructured":"Iannacone M, Sitia G, Ruggeri ZM, Guidotti LG. HBV pathogenesis in animal models: recent advances on the role of platelets. J Hepatol. 2007;46(4):719\u201326.","journal-title":"J Hepatol."},{"key":"112_CR24","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(70)90926-8","volume":"1","author":"DS Dane","year":"1970","unstructured":"Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet. 1970;1:695\u20138.","journal-title":"Lancet"},{"key":"112_CR25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/emboj\/16.1.59","volume":"16","author":"J Hu","year":"1997","unstructured":"Hu J, Toft DO, Seeger C. Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids. EMBO J. 1997;16:59\u201368.","journal-title":"EMBO J."},{"key":"112_CR26","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cld.2004.02.006","volume":"8","author":"CT Wai","year":"2004","unstructured":"Wai CT, Fontana RJ. Clinical significance of hepatitis B virus genotypes, variants, and mutants. Clin Liver Dis. 2004;8:321\u201352.","journal-title":"Clin Liver Dis."},{"key":"112_CR27","doi-asserted-by":"crossref","first-page":"32617","DOI":"10.1074\/jbc.271.51.32617","volume":"271","author":"X Wei","year":"1996","unstructured":"Wei X, Peterson DL. Expression, purification, and characterization of an active Rnase H domain of the hepatitis B viral polymerase. J Biol Chem. 1996;271:32617\u201322.","journal-title":"J Biol Chem."},{"key":"112_CR28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2893.2007.00915.x","volume":"14","author":"F Zoulim","year":"2007","unstructured":"Zoulim F, Buti M, Lok AS. Antiviral-resistant hepatitis B virus: can we prevent this monster for growing? J Viral Hepat. 2007;14:29\u201336.","journal-title":"J Viral Hepat."},{"key":"112_CR29","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0140-6736(90)91874-A","volume":"336","author":"WF Carman","year":"1990","unstructured":"Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet. 1990;336:325\u20139.","journal-title":"Lancet"},{"key":"112_CR30","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/hep.510270144","volume":"27","author":"SA Locarnini","year":"1998","unstructured":"Locarnini SA. Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance. Hepatology. 1998;27:294\u20137.","journal-title":"Hepatology"},{"key":"112_CR31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1386-6532(02)00049-5","volume":"25","author":"J Torresi","year":"2002","unstructured":"Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol. 2002;25:97\u2013106.","journal-title":"J Clin Virol."},{"key":"112_CR32","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1128\/JCM.00057-06","volume":"44","author":"ML Cuestas","year":"2006","unstructured":"Cuestas ML, Mathet VL, Ruiz V, Minassian ML, Rivero C, Sala A, et al. Unusual naturally occurring humoral and cellular mutated epitopes of hepatitis B virus in a chronically infected Argentine patient with anti-HBs antibodies. J Clin Microbiol. 2006;44:2191\u20138.","journal-title":"J Clin Microbiol."},{"key":"112_CR33","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1099\/0022-1317-65-3-651","volume":"65","author":"A Dejean","year":"1984","unstructured":"Dejean A, Lugassy C, Zafrani S, Tiollais P, Brechot C. Detection of hepatitis B virus DNA in p\u00e1ncreas, kidney and skin of two human carriers of the virus. J Gen Virol. 1984;65:651\u20135.","journal-title":"J Gen Virol."},{"key":"112_CR34","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1128\/JCM.28.12.2850-2852.1990","volume":"28","author":"AM Bisceglie Di","year":"1990","unstructured":"Di Bisceglie AM, Hoofnagle JH. Hepatitis B virus replication within the human spleen. J Clin Microbiol. 1990;28:2850\u20132.","journal-title":"J Clin Microbiol."},{"key":"112_CR35","doi-asserted-by":"crossref","first-page":"15093","DOI":"10.1053\/j.gastro.2009.08.063","volume":"137","author":"F Zoulim","year":"2009","unstructured":"Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137:15093\u20131608.","journal-title":"Gastroenterology"},{"issue":"1","key":"112_CR36","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1128\/AAC.46.1.82-88.2002","volume":"46","author":"PL Marion","year":"2002","unstructured":"Marion PL, Salazar FH, Winters MA, Colonno RJ. Potency efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob Agents Chemother. 2002;46(1):82\u20138.","journal-title":"Antimicrob Agents Chemother."},{"key":"112_CR37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1582-4934.2002.tb00317.x","volume":"6","author":"C Kreutz","year":"2002","unstructured":"Kreutz C. Molecular, immunological and clinical properties of mutated hepatitis B viruses. J Cell Mol Med. 2002;6:113\u201343.","journal-title":"J Cell Mol Med."},{"key":"112_CR38","first-page":"277","volume-title":"Progress in Hepatitis B Research","author":"VL Mathet","year":"2007","unstructured":"Mathet VL, Cuestas ML, Trinks J, Minassian ML, Ruiz V, Rivero CW, et al. Genetic diversity and variability of Hepatitis B Virus (HBV) in Latin America and the Caribbean region: implications in epidemiological, clinical, diagnostic, prophylactic and therapeutic approaches. In: Denyer DV, editor. Progress in Hepatitis B Research. New York: Nova Science; 2007. p. 277\u2013351."},{"key":"112_CR39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1128\/AAC.45.1.229-235.2001","volume":"45","author":"ML Bryant","year":"2001","unstructured":"Bryant ML, Bridges EG, Placidi L, Faraj A, Loi A-G, Pierra C, et al. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents and Chemother. 2001;45:229\u201335.","journal-title":"Antimicrob Agents and Chemother."},{"key":"112_CR40","first-page":"87","volume-title":"Progress in hepatitis B research","author":"B Agrawal","year":"2007","unstructured":"Agrawal B, Srivastay NC, Kumar R. Progress in the chemo-and immune-therapeutic interventions for hepatitis B virus. In: Denyer DV, editor. Progress in hepatitis B research. New York: Nova Science; 2007. p. 87\u2013112."},{"key":"112_CR41","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jhep.2003.09.022","volume":"39","author":"JP Villeneuve","year":"2003","unstructured":"Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol. 2003;39:1085\u20139.","journal-title":"J Hepatol."},{"key":"112_CR42","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1172\/JCI11100","volume":"107","author":"SK Ono","year":"2001","unstructured":"Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest. 2001;107:449\u201355.","journal-title":"J Clin Invest."},{"key":"112_CR43","doi-asserted-by":"crossref","first-page":"11833","DOI":"10.1128\/JVI.77.21.11833-11841.2003","volume":"77","author":"WE Delaney 4th","year":"2003","unstructured":"Delaney 4th WE, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol. 2003;77:11833\u201341.","journal-title":"J Virol."},{"key":"112_CR44","first-page":"281A","volume":"24","author":"RJ Gilson","year":"1996","unstructured":"Gilson RJ, Chopra KB, Newell AM, Murray-Lyon IM, Nelson MR, Tedder RS, et al. A placebo-controlled phase I\/II study of adefovir dipivoxil (bis-POM PMEA) in patients with chronic hepatitis B infection. Hepatology. 1996;24:281A.","journal-title":"Hepatology"},{"key":"112_CR45","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/MJT.0b013e318155a191","volume":"15","author":"E Palumbo","year":"2008","unstructured":"Palumbo E. New drugs for chronic hepatitis B: a review. Am J Ther. 2008;15:167\u201372.","journal-title":"Am J Ther."},{"key":"112_CR46","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/hep.21422","volume":"44","author":"RJ Colonno","year":"2006","unstructured":"Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowsky K, Yu CF, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology. 2006;44:1656\u201365.","journal-title":"Hepatology"},{"key":"112_CR47","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/j.1365-2893.2007.00877.x","volume":"14","author":"R Jardi","year":"2007","unstructured":"Jardi R, Rodriguez-Frias F, Schaper M, Ruiz G, Elefsiniotis I, Esteban R, et al. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-na\u00efve patients. J Viral Hepat. 2007;14:835\u201340.","journal-title":"J Viral Hepat."},{"key":"112_CR48","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/j.clinthera.2007.12.032","volume":"29","author":"SJ Matthews","year":"2007","unstructured":"Matthews SJ. Telbivudine for the management of chronic hepatitis B. Clin Ther. 2007;29:2635\u201353.","journal-title":"Clin Ther."},{"key":"112_CR49","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1517\/17425255.4.10.1351","volume":"4","author":"YY Lui","year":"2008","unstructured":"Lui YY, Chan HL. A review of telbivudine for the management of chronic hepatitis B virus infection. Expert Opin Drug Metab Toxicol. 2008;4:1351\u201361.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"112_CR50","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","volume":"359","author":"P Marcellin","year":"2008","unstructured":"Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442\u201355.","journal-title":"N Engl J Med."},{"key":"112_CR51","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s12072-008-9046-5","volume":"2","author":"T Piratvisuth","year":"2008","unstructured":"Piratvisuth T. Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B. Hepatol Int. 2008;2:140\u20136.","journal-title":"Hepatol Int."},{"key":"112_CR52","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.antiviral.2007.10.014","volume":"77","author":"Y-F Yang","year":"2008","unstructured":"Yang Y-F, Zhao W, Zhong Y-D, Yang Y-J, Shen L, Zhang N, et al. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: A meta-analysis. Antiviral Res. 2008;77:136\u201341.","journal-title":"Antiviral Res."},{"key":"112_CR53","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2893.2005.00624.x","volume":"12","author":"A Kramvis","year":"2005","unstructured":"Kramvis A, Kew MC. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J Viral Hepat. 2005;12:456\u201364.","journal-title":"J Viral Hepat."},{"key":"112_CR54","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/hep.510310323","volume":"31","author":"A Erhardt","year":"2000","unstructured":"Erhardt A, Reineke U, Blondin D, Gerlich WH, Adams O, Heintges T, et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology. 2000;31:716\u201325.","journal-title":"Hepatology"},{"key":"112_CR55","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0168-8278(00)80135-X","volume":"33","author":"JH Kao","year":"2000","unstructured":"Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol. 2000;33:998\u20131002.","journal-title":"J Hepatol."},{"issue":"Suppl 1","key":"112_CR56","first-page":"125","volume":"29","author":"GK Lau","year":"2009","unstructured":"Lau GK. HBe Ag-positive chronic hepatitis B: why do I treat my patients with pegylated interferon? Liver Int. 2009;29 Suppl 1:125\u20139.","journal-title":"Liver Int."},{"key":"112_CR57","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2165\/00003495-199753010-00005","volume":"53","author":"G Saracco","year":"1997","unstructured":"Saracco G, Rizzetto M. A practical guide to the use of interferons in the management of hepatitis virus infections. Drugs. 1997;53:74\u201385.","journal-title":"Drugs"},{"issue":"4","key":"112_CR58","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1086\/511042","volume":"44","author":"H Zhao","year":"2007","unstructured":"Zhao H, Kurbanov F, Wan MB. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated\/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis. 2007;44(4):541\u20138.","journal-title":"Clin Infect Dis."},{"key":"112_CR59","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/jhep.2001.26371","volume":"34","author":"KL Lindsay","year":"2001","unstructured":"Lindsay KL, Tr\u00e9po C, Heintges T, Shiffman ML, Gordon SC, Schiff ER, et al. and J.K. Albrecht; Hepatitis Interventional Therapy Group. A randomized, double-blind trial comparing pegylated interferon alpha-2b to interferon alpha-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34:395\u2013403.","journal-title":"Hepatology"},{"key":"112_CR60","first-page":"369","volume":"7","author":"JL Poo","year":"2009","unstructured":"Poo JL, S\u00e1nchez \u00c1vila F, Kershenobich D, Garc\u00eda Samper X, Torres-Ibarra R, G\u00f3ngora J, et al. Efficacy of triple therapy with thymalfasin, peginterferon \u03b1-2a, and ribavirin for the treatment of hispanic chronic HCV non responders. Ann Hepatol. 2009;7:369\u201375.","journal-title":"Ann Hepatol."},{"key":"112_CR61","first-page":"87","volume-title":"Progress in hepatitis B research","author":"SK Yoon","year":"2007","unstructured":"Yoon SK. Immune-based therapy for chronic hepatitis B virus infection. In: Denyer DV, editor. Progress in hepatitis B research. New York: Nova Sciences; 2007. p. 87\u2013112."},{"key":"112_CR62","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1021\/bc700193d","volume":"18","author":"KC Chimalakonda","year":"2007","unstructured":"Chimalakonda KC, Agarwal HK, Kumar A, Parang K, Mehvar R. Synthesis, analysis, in vitro characterization, and in vivo disposition of a lamivudine-dextran conjugate for selective antiviral delivery to the liver. Bioconjugate Chem. 2007;18:2097\u2013108.","journal-title":"Bioconjugate Chem."},{"key":"112_CR63","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0092-8674(80)90116-6","volume":"21","author":"DA Wall","year":"1980","unstructured":"Wall DA, Wilson G, Ann L. Hubbard. The galactose-specific recognition system of mammalian liver: The route of ligand internalization in rat hepatocytes. Cell. 1980;21:79\u201393.","journal-title":"Cell"},{"key":"112_CR64","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/0167-4889(85)90160-0","volume":"847","author":"G Kempka","year":"1985","unstructured":"Kempka G, Kolb-Bachofen V. Galactose-specific receptors on liver cells. I. Hepatocyte and liver macrophage receptors differ in their membrane anchorage. Biochim Biophys Acta-Mol Cell Res. 1985;847:108\u201314.","journal-title":"Biochim Biophys Acta-Mol Cell Res."},{"key":"112_CR65","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1046\/j.1365-2893.1997.00067.x","volume":"4","author":"L Fiume","year":"1997","unstructured":"Fiume L, Di Stefano G, Busi C, Mattioli A, Bonino F, Torrani-Cerenzia M, et al. Liver targeting of antiviral nucleoside analogues through the asialoglycoprotein receptor. J Viral Hepat. 1997;4:363\u201370.","journal-title":"J Viral Hepat."},{"key":"112_CR66","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/8462","volume":"5","author":"E Toshiharu","year":"1999","unstructured":"Toshiharu E, Takahashi H. Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon. Nat Med. 1999;5:577\u201381.","journal-title":"Nat Med."},{"key":"112_CR67","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1136\/gut.25.12.1392","volume":"25","author":"L Fiume","year":"1984","unstructured":"Fiume L, Mattioli A, Busi C, Accorsi C. Selective penetration and pharmacological activity of lactosaminated albumin conjugates of adenine arabinoside 5-monophosphate (ara-AMP) in mouse liver. Gut. 1984;25:1392\u20138.","journal-title":"Gut"},{"key":"112_CR68","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/0006-2952(86)90084-5","volume":"35","author":"L Fiume","year":"1986","unstructured":"Fiume L, Bassi B, Busi C, Mattioli A, Spinosa G. Drug targeting in antiviral chemotherapy. A chemically stable conj\u00fagate of 9-\u03b2-D arabinofuranosyladenine 5\u2032-monophosphate with lactosaminated albumin accomplishes a selective delivery of the drug to liver cells. Biochem Pharmacol. 1986;35:967\u201372.","journal-title":"Biochem Pharmacol."},{"key":"112_CR69","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0169-409X(94)90005-1","volume":"14","author":"L Fiume","year":"1994","unstructured":"Fiume L, Busi C, Di Stefano G, Mattioli A. Targeting of antiviral drugs to the liver using glycoprotein carriers. Adv Drug Deliv Rev. 1994;14:51\u201365.","journal-title":"Adv Drug Deliv Rev."},{"key":"112_CR70","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0014-5793(86)80742-6","volume":"203","author":"L Fiume","year":"1986","unstructured":"Fiume L, Bassi B, Busi C, Mattioli A, Spinosa G, Faulstich H. Galactosylated poly(L-lysine) as a hepatotropic carrier of 9-beta-D-arabinofuranosyladenine 5\u2032-monophosphate. FEBS Lett. 1986;203:203\u20136.","journal-title":"FEBS Lett."},{"key":"112_CR71","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0168-8278(94)80243-2","volume":"21","author":"EA Biesen","year":"1994","unstructured":"Biesen EA, Beauting DM, Vietsch H, Bijsterbosch MK, Van Berkel TJ. Specific targeting of the antiviral drug 5-iodo 2\u2032-deoxyuridine to the parenchymal liver cell using lactosylated poly-L-lysine. J Hepatol. 1994;21:806\u201315.","journal-title":"J Hepatol."},{"key":"112_CR72","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0168-8278(97)80038-4","volume":"26","author":"L Fiume","year":"1997","unstructured":"Fiume L, Di Stefano G, Busi C, Mattioli A, Battista Gervasi G, Bertini M, et al. Hepatotropic conjugate of adenine arabinoside monophosphate with lactosaminated poly-L-lysine. Synthesis of the carrier and pharmacological properties of the conjugate. J Hepatol. 1997;26:253\u20139.","journal-title":"J Hepatol."},{"key":"112_CR73","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0168-3659(92)90079-7","volume":"19","author":"F Hudecz","year":"1992","unstructured":"Hudecz F, Ga\u00e1l D, Kurucz I, L\u00e1nyi \u00c1, Kov\u00e1cs AL, Mez\u00f6 G, et al. Carrier design: cytotoxicity and immunogenicity of synthetic branched polypeptides with poly(L-lysine) backbone. J Control Release. 1992;19:231\u201343.","journal-title":"J Control Release"},{"key":"112_CR74","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1177\/095632029700800606","volume":"8","author":"L Cui","year":"1997","unstructured":"Cui L, Faraj A, El Aloui AM, Groman EV, Rutkowski JV, Josephson L, et al. Arabinogalactan (9\u00a0kDa)-9-\u03b2-D-arabinofuranosyladenine-5\u2032-monophosphate, a novel liver-targeted conjugate that selectively inhibits hepatitis B virus replication in vitro. Antiv Chem Chemother. 1997;8:529\u201336.","journal-title":"Antiv Chem Chemother."},{"key":"112_CR75","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1021\/ja031818y","volume":"126","author":"MD Erion","year":"2004","unstructured":"Erion MD, Reddy KR, Boyer SH, Matelich MC, G\u00f3mez-Galeno J, Lemus RH, et al. Design, synthesis, and characterization of a series of cytochrome P450 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver. J Am Chem Soc. 2004;126:5154\u201363.","journal-title":"J Am Chem Soc."},{"key":"112_CR76","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1124\/jpet.104.075903","volume":"312","author":"MD Erion","year":"2005","unstructured":"Erion MD, van Poelje PD, MacKenna DA, Colby TJ, Montag AC, Fujitaki JM, et al. Liver-targeted drug delivery using HepDirect prodrugs. J Pharmacol Exp Ther. 2005;312:554\u201360.","journal-title":"J Pharmacol Exp Ther."},{"key":"112_CR77","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1081\/NCN-200059781","volume":"24","author":"KR Reddy","year":"2005","unstructured":"Reddy KR, Colby TJ, Fujitaki JM, van Poelje PD, Erion MD. Liver targeting of hepatitis B virus antiviral lamivudine using the HepDirect prodrug technology. Nucleosides Nucleotides Nucleic Acids. 2005;24:375\u201381.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"112_CR78","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0168-3659(91)90033-A","volume":"16","author":"S Vansteenkiste","year":"1991","unstructured":"Vansteenkiste S, Schacht E, Duncan R, Seymour L, Pawluczyk I, Baldwin R. Fate of glycosylated dextrans after in vivo administration. J Control Release. 1991;16:91\u2013100.","journal-title":"J Control Release"},{"key":"112_CR79","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1023\/A:1018949109004","volume":"10","author":"M Nishikawa","year":"1993","unstructured":"Nishikawa M, Kamijo A, Fujita T, Takakura Y, Sezaki H, Hashida M. Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxymethyl-dextran, and its application to drug targeting. Pharm Res. 1993;10:1253\u201361.","journal-title":"Pharm Res."},{"key":"112_CR80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.2042-7158.1988.tb05139.x","volume":"40","author":"S Nakane","year":"1987","unstructured":"Nakane S, Matsumoto S, Takakura Y, Hashida M, Sezaki H. The accumulation mechanism of cationic mitomycin c\u2013dextran conjugates in the liver: in-vivo cellular localization and in-vitro interaction with hepatocytes. J Pharm Pharmacol. 1987;40:1\u20136.","journal-title":"J Pharm Pharmacol."},{"key":"112_CR81","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0378-5173(90)90003-M","volume":"65","author":"K Nishida","year":"1990","unstructured":"Nishida K, Tonegawa C, Nakane S, Takakura Y, Hashida M, Sezaki H. Effect of electric charge on the hepatic uptake of macromolecules in the rat liver. Int J Pharm. 1990;65:7\u201317.","journal-title":"Int J Pharm."},{"key":"112_CR82","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1096\/fj.99-0887com","volume":"14","author":"EAL Biessen","year":"2000","unstructured":"Biessen EAL, Valentijn ARPM, De Vrueh RLA, Van De Bilt E, Sliedregt LAJM, Prince P, et al. Novel hepatotrophic prodrugs of the antiviral nucleoside 9-(2-phosphonylmethoxyethyl)adenine with improved pharmacokinetics and antiviral activity. FASEB J. 2000;14:1784\u201392.","journal-title":"FASEB J"},{"key":"112_CR83","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s12272-008-1121-x","volume":"31","author":"S Kim","year":"2008","unstructured":"Kim S, Jeong JM, Hong MK, Jang J-J, Lee J, Lee DS, et al. Differential receptor targeting of liver cells using 99mTc-neoglycosylated human serum albumins. Arch Pharm Res. 2008;31:60\u20136.","journal-title":"Arch Pharm Res."},{"key":"112_CR84","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1517\/17425240802622096","volume":"6","author":"T Kasuya","year":"2009","unstructured":"Kasuya T, Kuroda S. Nanoparticles for human liver-specific drug and gene delivery systems: in vitro and in vivo advances. Expert Opin Drug Deliv. 2009;6:39\u201352.","journal-title":"Expert Opin Drug Deliv."},{"key":"112_CR85","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/10611860802200938","volume":"16","author":"M Feng","year":"2008","unstructured":"Feng M, Cai Q, Shi X, Huang H, Zhou P, Guo X. Recombinant high-density lipoprotein complex as a targeting system of nosiheptide to liver cells. J Drug Target. 2008;16:502\u20138.","journal-title":"J Drug Target."},{"key":"112_CR86","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1126\/science.271.5248.518","volume":"271","author":"S Acton","year":"1996","unstructured":"Acton S, Rigotti A, Landschulz KT. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996;271:518\u201320.","journal-title":"Science"},{"key":"112_CR87","first-page":"661","volume":"28","author":"Q Wei","year":"1996","unstructured":"Wei Q, Wu MP, Chen PF. Cooperation of HDL receptor and hepatic lipase in the selectve uptake of HDL2-CE by rat hepatic sinusoidal cells. Acta Biochem Biophys Sinica. 1996;28:661\u20134.","journal-title":"Acta Biochem Biophys Sinica"},{"key":"112_CR88","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nature01250","volume":"421","author":"LO Martinez","year":"2003","unstructured":"Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabez\u00f3n E, Champagne E, et al. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature. 2003;421:75\u20139.","journal-title":"Nature"},{"key":"112_CR89","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ejpb.2007.07.005","volume":"68","author":"M Feng","year":"2008","unstructured":"Feng M, Cai Q, Huang H, Zhou P. Liver targeting and anti-HBV activity of reconstituted HDL-acyclovir palmitate complex. Eur J Pharm Biopharm. 2008;68:688\u201393.","journal-title":"Eur J Pharm Biopharm."},{"key":"112_CR90","first-page":"853","volume":"44","author":"J Miao","year":"2009","unstructured":"Miao J, Jiang X-G, Li S-PM-W, Hu F-Q, Du Y-Z. Antiviral effect of adefovir dipivoxil loaded solid lipid nanoparticles in vitro. Chin Pharm J. 2009;44:853\u20136.","journal-title":"Chin. Pharm J."},{"key":"112_CR91","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/317489a0","volume":"317","author":"P Tiollais","year":"1985","unstructured":"Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature. 1985;317:489\u201395.","journal-title":"Nature"},{"key":"112_CR92","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jconrel.2006.12.020","volume":"118","author":"T Nagaoka","year":"2007","unstructured":"Nagaoka T, Fukuda T, Yoshida S, Nishimura H, Yu D, Kuroda S, et al. Characterization of bio-nanocapsule as a transfer vector targeting human hepatocyte carcinoma by disulfide linkage modification. J Control Release. 2007;118:348\u201356.","journal-title":"J Control Release"},{"key":"112_CR93","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jconrel.2006.11.006","volume":"117","author":"Y Zhang","year":"2007","unstructured":"Zhang Y, Qi XR, Gao Y, Wei L, Maitani Y, Nagai T. Mechanisms of co-modified liver-targeting liposomes as gene delivery carriers based on cellular uptake and antigens inhibition effect. J Control Release. 2007;117:281\u201390.","journal-title":"J Control Release"},{"key":"112_CR94","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.3748\/wjg.15.1805","volume":"15","author":"EB Keffee","year":"2009","unstructured":"Keffee EB, Rossignol J-F. Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides. World J Gastroenterol. 2009;15:1805\u20138.","journal-title":"World J Gastroenterol."},{"key":"112_CR95","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1261\/rna.459807","volume":"13","author":"D Paula de","year":"2007","unstructured":"de Paula D, Bentley MV, Mahato RI. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA. 2007;13:431\u201352.","journal-title":"RNA"},{"key":"112_CR96","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11095-007-9504-0","volume":"25","author":"Y Chen","year":"2008","unstructured":"Chen Y, Cheng G, Mahato RI. RNAi for treating hepatitis B viral infection. Pharm Res. 2008;25:72\u201386.","journal-title":"Pharm Res."},{"key":"112_CR97","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/jgm.1202","volume":"10","author":"RE Vandenbroucke","year":"2008","unstructured":"Vandenbroucke RE, Bonn\u00e9 S, Vinken M, Van Haecke T, Heimberg H, Wagner E, et al. Prolonged gene silencing in hepatoma cells and primary hepatocytes after small interfering RNA delivery with biodegradable poly(\u03b2-amino esters). J Gene Med. 2008;10:783\u201394.","journal-title":"J Gene Med."},{"key":"112_CR98","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/j.1745-7254.2008.00891.x","volume":"29","author":"J Fu","year":"2008","unstructured":"Fu J, Tang ZM, Gao X, Zhao F, Zhong H, Wen MR, et al. Optimal design and validation of antiviral siRNA for targeting hepatitis B. Acta Pharmacol Sin. 2008;29:1522\u20138.","journal-title":"Acta Pharmacol Sin."},{"key":"112_CR99","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.3748\/wjg.14.3849","volume":"14","author":"X-M Xin","year":"2008","unstructured":"Xin X-M, Li G-Q, Jin Y-Y, Zhuang M, Li D. Combination of small interfering RNAs mediates greater supression on hepatitis B virus cccDNA in HepG2.2.15 cells. World J Gastroenterol. 2008;14:3849\u201354.","journal-title":"World J Gastroenterol."},{"key":"112_CR100","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1021\/mp800157x","volume":"6","author":"S Carmona","year":"2008","unstructured":"Carmona S, Jorgensen MR, Kolli S, Crowther C, Salazar FH, Marion PL, et al. Controlling HBV replication in vivo by intravenous administration of triggered pegylated siRNA-nanoparticles. Mol Pharm. 2008;6:706\u201317.","journal-title":"Mol Pharm."},{"key":"112_CR101","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00430-008-0101-6","volume":"198","author":"K-F Tang","year":"2009","unstructured":"Tang K-F, Chen M, Xie J, Song G-B, Shi Y-S, Liu Q, et al. Inhibition of hepatitis B virus replication by small interference RNA induces expression of MICA in HepG2.2.15. Med Microbiol Immunol. 2009;198:27\u201332.","journal-title":"Med Microbiol Immunol."},{"key":"112_CR102","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s12272-009-1714-z","volume":"32","author":"H-A Cho","year":"2009","unstructured":"Cho H-A, Park I-S, Kim T-W, Oh Y-K, Yang K-S, Kim J-S. Supression of hepatitis B virus-derived human hepatocellular carcinoma by NF-\u03baB-inducing kinase-specific siRNA using liver-targeting liposomes. Arch Pharm Res. 2009;32:1077\u201386.","journal-title":"Arch Pharm Res."},{"key":"112_CR103","first-page":"2179","volume":"42","author":"RW King","year":"1998","unstructured":"King RW, Ladner SK, Miller TJ, Zaifert K, Perni RB, Conway SC, et al. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone an in combination with (-)\u03b2-L-2\u2032, 3\u2032-dideoxi-3\u2032-thiacytidine. Antimicrob Agents Chemother. 1998;42:2179\u20133186.","journal-title":"Antimicrob Agents Chemother."},{"key":"112_CR104","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1128\/AAC.46.9.3057-3060.2002","volume":"46","author":"WE Delaney IV","year":"2002","unstructured":"Delaney IV WE, Edwards R, Colledge D, Shaw T, Furman P, Painter G, et al. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine resistant starins of hepatitis B virus in vitro. Antimicrob Agents Chemother. 2002;46:3057\u201360.","journal-title":"Antimicrob Agents Chemother."},{"key":"112_CR105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/aps.2008.5","volume":"30","author":"C Wohlfarth","year":"2009","unstructured":"Wohlfarth C, Efferth T. Natural products as promising drug candidates for the treatment of hepatitis B and C. Acta Pharmacol Sin. 2009;30:25\u201330.","journal-title":"Acta Pharmacol Sin."},{"key":"112_CR106","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2174\/157340609787049316","volume":"5","author":"GT Liu","year":"2009","unstructured":"Liu GT. Bicyclol: a novel drug for treating chronic viral hepatitis B and C. Med Chem. 2009;5:29\u201343.","journal-title":"Med Chem."},{"key":"112_CR107","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1073\/pnas.96.6.2758","volume":"96","author":"DJ Segal","year":"1999","unstructured":"Segal DJ, Dreier B, Beerli RR, Barbas III CF. Toward controlling gene expression at will: selection and design of zinc finger domains recognizing each of the 5\u2032-GNN-3\u2032DNA target sequences. Proc Natl Acad Sci USA. 1999;96:2758\u201363.","journal-title":"Proc Natl Acad Sci USA."},{"key":"112_CR108","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1124\/mol.104.002758","volume":"66","author":"P Blancafort","year":"2004","unstructured":"Blancafort P, Segal DJ, Barbas III CF. Designing transcription factors architectures for drug discovery. Mol Pharmacol. 2004;66:1361\u201371.","journal-title":"Mol Pharmacol."},{"key":"112_CR109","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/10611860600942178","volume":"15","author":"JM Lanao","year":"2007","unstructured":"Lanao JM, Briones E, Colino CI. Recent advances in delivery systems for anti-HIV1 therapy. J Drug Target. 2007;15:21\u201336.","journal-title":"J Drug Target."},{"key":"112_CR110","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.2165\/00003495-200767130-00015","volume":"67","author":"VR Anderson","year":"2007","unstructured":"Anderson VR, Curran MP. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs. 2007;67:1947\u201367.","journal-title":"Drugs"},{"key":"112_CR111","first-page":"1151A","volume":"48","author":"M Elazar","year":"2008","unstructured":"Elazar M, Liu M, McKenna S, Liu P, Gehrig EA, Elfert A, et al. Nitazoxanide (NTZ) is an inducer of eIF2a and PKR phosphorylation. Hepatology. 2008;48:1151A.","journal-title":"Hepatology"},{"key":"112_CR112","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.antiviral.2007.08.005","volume":"77","author":"BE Korba","year":"2008","unstructured":"Korba BE, Montero AB, Farrar K, Gaye K, Mukerjee S, Ayers MS, et al. Nitazoxanide, tizoxanide and other thiazolides are potents inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res. 2008;77:56\u201363.","journal-title":"Antiviral Res."},{"key":"112_CR113","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.14309\/00000434-200809001-00390","volume":"103","author":"WZ Kolozsi","year":"2008","unstructured":"Kolozsi WZ. Y. El.Gohary, E.B. Keeffe, and J.F. Rossignol. Treatment of chronic hepatitis B (CHB) with nitazoxanide (NTZ) alone or NTZ plus adefovir (ADV) for two years with loss of hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg): report of two cases. Am J Gastroenterol. 2008;103:S150\u20131.","journal-title":"Am J Gastroenterol."},{"key":"112_CR114","first-page":"373","volume":"22","author":"W Ting","year":"1997","unstructured":"Ting W, Hai H, Pei Z. The inhibitory effects of nosiheptide on hepatitis B virus in vitro. Chin J Antibiot. 1997;22:373\u20136.","journal-title":"Chin J Antibiot."},{"key":"112_CR115","first-page":"462","volume":"40","author":"Q-S Cai","year":"2005","unstructured":"Cai Q-S, Huang H, Feng M-Q, Zhou P. Preparation of nosiheptide liposomes and its inhibitory effect on hepatics B virus in vitro. Yaoxue Xuebao. 2005;40:462\u20135.","journal-title":"Yaoxue Xuebao"},{"key":"112_CR116","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/sj.mt.6300168","volume":"15","author":"SI Kim","year":"2007","unstructured":"Kim SI, Shin D, Choi TH, Lee JC, Cheon GJ, Kim KY, et al. Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I. Mol Ther. 2007;15:1145\u201352.","journal-title":"Mol Ther."},{"key":"112_CR117","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/mt.2008.14","volume":"16","author":"K Nishina","year":"2008","unstructured":"Nishina K, Unno T, Uno Y, Kubodera T, Kanouchi T, Mizusawa H, et al. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha tocopherol. Mol Ther. 2008;16:734\u201340.","journal-title":"Mol Ther."},{"key":"112_CR118","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nbt1396","volume":"26","author":"Y Sato","year":"2008","unstructured":"Sato Y, Murase K, Kato J, Kobune M, Sato T, Kawano Y, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol. 2008;26:431\u201342.","journal-title":"Nat Biotechnol."},{"key":"112_CR119","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/nbt1122","volume":"23","author":"DV Morrisey","year":"2005","unstructured":"Morrisey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol. 2005;23:1002\u20137.","journal-title":"Nat Biotechnol."},{"key":"112_CR120","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/j.bcp.2003.08.001","volume":"66","author":"HJ Hacker","year":"2003","unstructured":"Hacker HJ, Deres K, Mildenberger M, Schr\u00f6der CH. Antivirals interacting with hepatitis B virus core protein and core mutations may misdirect capsid assembly in a similar fashion. Biochem Pharmacol. 2003;66:2273\u20139.","journal-title":"Biochem Pharmacol."},{"key":"112_CR121","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1053\/j.gastro.2007.02.039","volume":"132","author":"M Ghany","year":"2007","unstructured":"Ghany M, Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology. 2007;132:1574\u201385.","journal-title":"Gastroenterology"},{"key":"112_CR122","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s000180050296","volume":"55","author":"B Weiss","year":"1999","unstructured":"Weiss B, Davidkova G, Zhou L-W. Antisense RNA gene therapy for studying and modulating biological processes. Cell Mol Life Sci. 1999;55:334\u201358.","journal-title":"Cell Mol Life Sci."},{"key":"112_CR123","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/10717540590968215","volume":"12","author":"J Shi","year":"2005","unstructured":"Shi J, Yan W-W, Qi X-R, Maitani Y, Nagal T. Characteristics and biodistribution of soybean sterylglucoside and polyethylene glycol-modified cationic liposomes and their complexes with antisense oligodeoxinucleotide. Drug Deliv. 2005;12:349\u201356.","journal-title":"Drug Deliv."},{"issue":"10","key":"112_CR124","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1128\/AAC.48.10.3702-3710.2004","volume":"48","author":"WE Delaney IV","year":"2004","unstructured":"Delaney IV WE, Yang H, Miller MD, Gibbs CS, Xiong S. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother. 2004;48(10):3702\u201310.","journal-title":"Antimicrob Agents Chemother."},{"key":"112_CR125","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S1473-3099(08)70102-6","volume":"8","author":"KL Nash","year":"2008","unstructured":"Nash KL, Alexander GJM. The case for combination antiviral therapy for chronic hepatitis B virus infection. Lancet Infect Dis. 2008;8:444\u20138.","journal-title":"Lancet Infect Dis."},{"key":"112_CR126","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","volume":"137","author":"F Zoulim","year":"2009","unstructured":"Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137:1593\u2013608.","journal-title":"Gastroenterology"},{"key":"112_CR127","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.addr.2009.11.010","volume":"62","author":"A Sosnik","year":"2010","unstructured":"Sosnik A, Amiji M. Nanotechnology solutions for infectious diseases in developing nations. Adv Drug Del Rev. 2010;62:375\u20137.","journal-title":"Adv Drug Del Rev."},{"key":"112_CR128","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2009.05.007","volume":"138","author":"A Sosnik","year":"2009","unstructured":"Sosnik A, Chiappetta DA, Carcaboso AM. Drug delivery systems in HIV pharmacotherapy: What has been done and the challenges standing ahead. J Control Release. 2009;138:2\u201315.","journal-title":"J Control Release"},{"key":"112_CR129","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.addr.2009.11.023","volume":"62","author":"A Sosnik","year":"2010","unstructured":"Sosnik A, Carcaboso AM, Glisoni RJ, Moretton MA, Chiappetta DA. New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery. Adv Drug Del Rev. 2010;62:547\u201359.","journal-title":"Adv Drug Del Rev."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-010-0112-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-010-0112-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-010-0112-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T08:43:33Z","timestamp":1711356213000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-010-0112-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,24]]},"references-count":129,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["112"],"URL":"https:\/\/doi.org\/10.1007\/s11095-010-0112-z","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,24]]}}}